In November 2017, Deerfield committed up to $240 million to Melinta Therapeutics to fund the acquisition of the infectious disease business from The Medicines Company. Melinta is a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections. The products acquired include Vabomere, Orbactiv and Minocin IV.
Neos Therapeutics, Inc. is a specialty pharmaceutical company with a late-stage pipeline of innovative extended release products for the treatment of ADHD. Neos has submitted an NDA for its methylphenidate XR-ODT drug candidate for ADHD medication based on its patented XR-ODT technology. Neos’ XR-ODT and XR-Liquid product candidates provide patient-friendly dosage forms for patients who have difficulty swallowing tablets or capsules and can benefit from extended- release formulations.